Phase 4RecruitingAge-related condition
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
BOOST-PD - Better On-time Observations of Motor Fluctuations Using Wearable Sensor Technology: A Naturalistic Study on IPX-203 for Parkinson's Disease
- Sponsor
- The Cleveland Clinic (Academic or other)
- Enrolment
- 22 planned
- Conditions
- Parkinson Disease
- Interventions
- CREXONT ER
- Ages
- adults, older adults
- Registry
- NCT07138560
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias. The change in the duration and quality of on-time will be measured by a wearable device placed on your wrist called KinesiaU.
Primary outcomes
- Primary Endpoint
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started